Results 131 to 140 of about 1,869 (168)
Early Experience of Lebrikizumabâ–¼ in the Treatment of Atopic Dermatitis
EMJ Dermatologyopenaire +1 more source
Managing Atopic Dermatitis With Lebrikizumab – The Evidence to Date
Clinical, Cosmetic and Investigational Dermatology, 2022 Atopic dermatitis is a prevalent, inflammatory skin disease that presents with an eczematous, itchy rash. As of late, there have been many emerging monoclonal antibody inhibitor and small molecule therapies that have changed the course of eczema treatment. One of the treatments in the pipeline for atopic dermatitis is interleukin 13 monoclonal antibody
Gil Yosipovitch, Teresa Ju
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Lebrikizumab Treatment in Adults With Asthma
New England Journal of Medicine, 2011Many patients with asthma have uncontrolled disease despite treatment with inhaled glucocorticoids. One potential cause of the variability in response to treatment is heterogeneity in the role of interleukin-13 expression in the clinical asthma phenotype.
Joseph R Arron +2 more
exaly +9 more sources
Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
New England Journal of Medicine, 2023Jashin J. Wu +2 more
exaly +3 more sources
Lebrikizumab for the Treatment of Asthma
Expert Opinion on Investigational Drugs, 2016In asthma, most commonly, 'conventional' anti-inflammatory medications represented by inhaled corticosteroids and leukotriene inhibitors are effective. In some patients however additional inhibition of the airways inflammation is necessary. Such compounds might be molecules inhibiting specifically certain inflammation pathways and lebrikizumab an anti ...
Sabina Antonela Antoniu
exaly +3 more sources